688639.SH
华恒生物
SSE · Healthcare · Biotechnology · CN
CNY 16.08
−3.65%Year over year
Reported trailing growth
- Revenue
- +24.6%
- EBITDA
- —
- EBIT
- -28.7%
- EPS
- -23.9%
- Free cash flow
- -20.5%
- Operating cash flow
- -68.1%
Forward estimates
Based on analyst estimates
- Revenue
- -39.5%
- EBITDA
- +17.2%
- EPS
- +51.8%
Three-year CAGR
- Revenue
- +26.4%
- EBITDA
- -4.4%
- EBIT
- -27.6%
- Net income
- -25.5%
- EPS
- -36.2%
- Free cash flow
- +26.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026